Replies to post #600347 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

OJ,

Fortunately the one who fronted $3m would not wait until the publication of the results on peer-reviewed journal trust what he/she sees.

It's not promotional. If it were promotional, the research on combination therapy would have been presented too.

One thing for sure what we have seem is just the tip of an iceberg. If they tested whether DCVax-L can be loaded with antigens from various solid tumors. Would they test DCVax-L alone and its combinations on animal models? Absolutely! Would they do the same ex vivo? Absolutely!
Tens of patients with different types tumors received the DCVax-L treatment through compassionate program. It could be DCVax-L alone or its combinations. If a rGBM patient who were supposed to go to hospice is still alive and there is no recurrence after receiving DCVax-L. What about patients with other tumors?

Now you are telling us that we should not be excited. We should be more excited than ever! Peer-reviewed publication will come sooner or later. It is just a matter of time and a formality.

[ae kusterer]

OncoJock: The 10 biggest cancer therapy players and CI manufacturers do not need a peer reviewed journal to tell thaem what startehgic moves they need tomake after DC VAX L gets MAA approval. THe quortes belwo reflect their current understanfing ofSCVAX L.



Au contraire, when the MIA was awarded on 3/20/23, the train left the station. That predestined MAA approval , which should arrive about 8/1/23. Everybody knew that the MAA award would precipitate 2 partnerships , and bids for NWBO by 5 of the biggest CI players. Net, net, NWBO change of control 30 days after the MAA award. But the Bosch MOA Bomb on 6/3/23 increases the bids to 10 within 30 days of the MAA award.Why? Because the big boys know the MOA Bosch described will revolutionize medicine. And it is moated by patents, proprietary manufacturing technology, and knowhow.


So bottom line, DCVax-L Cell Based Platform Technology is a developed process that allows medical science to Direct The Immune System in a general application for all diseases. It improves all existing treatments used in healthcare as we know it!!!In very simple terms, it is the APPLE of modern healthcare treatments!!!Cheers,BBBright BoyRe: Lykiri post# 600189Saturday, June 10, 2023 10:48:29 AMPost# of 600341

Prior to Marnix Bosch's ( CTO-NWBO) 6/3/23 ASCO presentation(lecture and slides) AVC (alphavestcapital.com) pointed out that the LIAU-UCLA-SPORE combination trial data showed that all CIs (checkpoint inhibitors) are more efficacious when dosed in combination with DCVax-L, and that some CIs do not work at all without DC VAX L. MRK's Keytruda( a CI with $21 billion in '22 revenues) is a good example. Keytruda as a mono therapy proved in five clinical trials that it did not increase efficacy, compared to SOC, in GBM. But when dosed in combination with DC VAX L , there was impressive efficacy .https://trp.cancer.gov/spores/abstracts/ucla_brain.htmBut on 6/3/23 at ASCO, Marnix Bosch presented data showing that DC VAX L is a process that can direct the immune system response to targets in all diseases, not just all solid tumor cancers. From conversations with our associates in Big Biotech and Pharma , they are shocked because they do not know how to do what NWBO has done .They know their portfolio of drugs will perform better when dosed with DC VAX L . Their attempts to replicate the manufacturing of DC VAX L have come up short . Plus they do not know how to get around the patent moat. They are left with attempting to buy NWBO, or invest in partnerships which will license them the rights to have access to the DC VAX L technology. What strategic moves are afoot
Dr. Bosch: „If you use a lysate from another tumor you get new antigens that are more appropriate to that particular tumor.“AGNOSTIC= "A type of therapy that uses drugs or other substances to treat cancer based on the cancer’s genetic and molecular features without regard to the cancer type or where the cancer started in the body. Tissue-agnostic therapy uses the same drug to treat all cancer types that have the genetic mutation (change) or biomarker that is targeted by the drug. It is a type of targeted therapy. Also called tumor-agnostic therapy."
0 Comments


"Dr. Bosch: „If you use a lysate from another tumor you get new antigens that are more appropriate to that particular tumor.“
AGNOSTIC= "A type of therapy that uses drugs or other substances to treat cancer based on the cancer’s genetic and molecular features without regard to the cancer type or where the cancer started in the body. Tissue-agnostic therapy uses the same drug to treat all cancer types that have the genetic mutation (change) or biomarker that is targeted by the drug. It is a type of targeted therapy. Also called tumor-agnostic therapy."
https://www.fda.gov/media/162346/download


ATL:"This MOA is not just specific to the brain, but should work for every organ in the human body."
BRIGHT BOY:" DCVax-L which provides the world of medicine the ability to DIRECT THE IMMUNE SYSTEM and thereby TARGET ALL DISEASES !!!!!!! In simple terms, DCVax-L is able to identify antigens, which in a perfect system, ARE NOT SUPPOSED TO BE THERE !!!! AND GET RID OF THEM!!!!!!!" "
https://nwbio.com/ (bosch slides and video)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172093346 (transcript)


So I'm going to go out on a limb here in my following comments, but I believe it's time and I believe the scientific/medical community is beginning to recognize that Northwest and it's brilliant team from Alton Boynton, Linda Powers, Dr. Bosch, Allen Turner( former NWBO employee), Dr. Linda Liau and her UCLA team, my friend that is truly a legend in the biotech world and everyone else involved in the development, discovery and understanding of the technology that drives the process that is DCVax-L , has provided the world of medicine with the ability to DIRECT THE IMMUNE SYSTEM and thereby TARGET ALL DISEASES!!!!!
In simple terms, DCVax-L is able to identify antigens, which in a perfect system, ARE NOT SUPPOSED TO BE THERE !!!! AND GET RID OF THEM!!!!!!!
AND Yes!!! You already know what this means !!! DCVax-L represents the platform technology that is a general application for all diseases !!!!!
Cheers,
BB

·
Jun 4
1/2 $NWBO Dr. Bosch’s presentation was a quiet K-Boom! In my opinion regarding T cell recruitment, activation, etc. But in particular one needs to comprehend T cell exhaustion in Cancers and in chronic viral infections (age and kill us). The clonal expansion found with DCVax
Gregory Zivic, MD
@metacollectiveG
·
Jun 4
$NWBO The “newly expanded” T cell clones I find particularly interesting. T Cell dysfunction and exhaustion cannot be overcome by PD-1 inhibition or Car-T (Car T cells themselves become exhausted and why this therapy has it’s drawbacks)
Gregory Zivic, MD
@metacollectiveG
·
Jun 4
2/2 $NWBO Also important was the finding that other Cancer antigens not previously found in GBM were found in the DCs after pulsing with Lysate. Also, viral antigens present. None of these have formally been found on GBM tumors before.
Gregory Zivic, MD
@metacollectiveG
·
Jun 4
$NWBO If anyone’s incapable of comprehending this take away one thing; what’s being shown here is the pivot toward how ALL disease will be treated and cured; all solid tumors, blood cancers, autoimmunity, viruses… incredible. Brilliance. https://nwbio.com/wp-content/uploads/NWBT_ASCO_slides_06032022_FINAL.pdfIn Reply to this message by




Re: CrashOverride post# 600284

Saturday, June 10, 2023 5:11:26 PM

Post#
600347
of 600397
Agreed.

So let me re-phrase what I wrote.

I will become more excited about these MOA data after they have been published in a peer-reviewed journal. Until then, the scientific information contained in this slide deck by Dr. Bosch remains of a highly technical and sophisticated but ultimately promotional nature, and it therefore lacks the credibility of other (peer-reviewed) data released at ASCO.

Or . . . . did I miss the part in his talk where he tells us these data have been, or will be, submitted for publication?

-- OJ